# **Financial Tearsheet**

## **Company Overview**

Endra is developing technology designed to increase the capabilities of clinical diagnostic ultrasound to broaden patient access to the safe diagnosis and treatment of a number of significant medical conditions in circumstances where expensive Xray computed tomography, or CT, and magnetic resonance imaging, or MRI, technology is unavailable or impractical.

### **Recent Financial News**

Date	Headline
Sep 01, 2016	ENDRA Life Sciences Adds Nexus 128+ to Their 3D Preclinical Photoacoustic CT Lineup
May 20, 2016	ENDRA Announces Partnership to Accelerate Development of ENDRA's Clinical Ultrasound Capabilities
Mar 10, 2016	ENDRA Life Sciences to Present at ROTH Capital Conference on March 15
Oct 19, 2015	ENDRA Life Sciences Announces Dr. Jing Gao as a Scientific Advisor
Aug 26, 2015	ENDRA Announces Jonathan Rubin, MD, PhD as a Scientific Advisor

#### IR Contacts

#### Leigh Salvo investors@endrainc.com 415-937-5403

## Stock Performance

No Fundamentals to display.

01/01/1970 12:00 AM ET			
Symbol			
Last Trade	\$0		
Change (%)	<b>1</b> 0 (0.00%)		
Volume	0		
Quotes delayed at least 20 mins.			

## **Recent XBRL Filings**

No SEC Filings to display.

#### Management Team

Francois Michelon, Chief Executive Officer and Chairman

Michael Thornton, Chief Technology Officer

David R. Wells, Chief Financial Officer (Interim)

#### Dr. Paul Picot, Chief Engineer

Board of Directors

Dr. Sanjiv Sam Gambhir, Director

Michael Harsh, Director

Alexander Tokman, Director